Sign in →

Test Code MUGS Hexosaminidase A, Serum

Reporting Name

Hexosaminidase A (MUGS), S

Useful For

Second-order test for diagnosing the B1 variant of Tay-Sachs disease

 

This test is not useful for testing for Sandhoff disease.

Testing Algorithm

For information see Tay-Sachs and Related Disorders Diagnostic Testing Algorithm

Method Name

Fluorometric

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Ordering Guidance


The following tests are available for diagnostic and carrier testing for Tay-Sachs and Sandhoff diseases:

NAGR / Hexosaminidase A and Total, Leukocytes/Molecular Reflex, Whole Blood

NAGW / Hexosaminidase A and Total Hexosaminidase, Leukocytes

NAGS / Hexosaminidase A and Total Hexosaminidase, Serum

MUGS / Hexosaminidase A, Serum

 

For information on hexosaminidase test selection see Hexosaminidase Test Selection Quick-Reference Comparison.



Necessary Information


Healthcare professional name and phone number are required.



Specimen Required


Patient Preparation:

Fasting: 4 hours, required; Infants and small children should have specimen collected before next feeding/meal

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL Serum

Collection Instructions: Centrifuge and aliquot serum into plastic vial.


Specimen Minimum Volume

Serum: 0.15 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Frozen (preferred) 365 days
  Refrigerated  5 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Plasma Reject

Reference Values

1.23-2.59 U/L (Normal)

1.16-1.22 U/L (Indeterminate)

0.58-1.15 U/L (Carrier)

Day(s) Performed

Friday

CPT Code Information

83080

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MUGS Hexosaminidase A (MUGS), S 2643-5

 

Result ID Test Result Name Result LOINC Value
80350 Hexosaminidase A (MUGS), S 2643-5

Clinical Information

Tay-Sachs and Sandhoff diseases, also referred to as GM2 gangliosidoses, are lysosomal storage disorders caused by deficiencies of hexosaminidase A and hexosaminidase B, respectively. These related enzymes are dimers that differ by subunit composition. Hexosaminidase A is a heterodimer composed of 1 alpha and 1 beta subunit, whereas hexosaminidase B is a homodimer composed of 2 beta subunits. The alpha subunit is encoded by the HEXA gene and the beta subunit is encoded by HEXB. Defective lysosomal degradation leads to excessive accumulation of GM2 ganglioside and related glycolipids, resulting in the clinical features associated with Tay-Sachs and Sandhoff diseases.

 

Both Tay-Sachs and Sandhoff diseases are inherited in an autosomal recessive manner. Tay-Sachs disease is caused by 2 disease-causing variants in HEXA, resulting in hexosaminidase A deficiency. An increased carrier frequency for Tay-Sachs disease is observed in individuals of Ashkenazi Jewish, Celtic, and French-Canadian ancestry. Sandhoff disease is caused by 2 disease-causing variants in HEXB, resulting in deficiencies of both hexosaminidase A and hexosaminidase B. Sandhoff disease does not exhibit an increased carrier frequency in any specific population. 

 

Clinical Phenotypes:

Phenotypically, patients with Tay-Sachs and Sandhoff diseases are virtually indistinguishable. Variability is observed with respect to age of onset and clinical symptoms. Enzyme analysis is generally required to distinguish between the 2 disorders.

 

The acute infantile forms of Tay-Sachs and Sandhoff diseases typically present with progressive motor deterioration beginning at 3 to 6 months of age. Patients exhibit weakness, hypotonia, and decreasing attentiveness. Motor skills learned previously, such as crawling or sitting alone, are nearly always lost by 1 year of age. Other symptoms include rapid diminishing of vision, seizures, macrocephaly due to cerebral gliosis, and the characteristic cherry-red spot in the retina. Affected individuals typically do not survive past early childhood.

 

The juvenile or subacute forms often present between 2 and 10 years of age with ataxia and clumsiness. Patients develop difficulties with speech and cognition. Neurologic features progressively get worse, and death typically occurs 2 to 4 years later.

 

Disease progression is slower in patients with chronic or adult-onset Tay-Sachs and Sandhoff diseases. Early signs and symptoms may be subtle and nonspecific, involving muscle and/or neurologic findings, often resulting in initial misdiagnoses. Affected individuals may exhibit abnormalities of gait and posture, spasticity, dysarthria, and progressive muscle wasting and weakness. Cognitive impairment, dementia, or psychiatric findings are observed in some patients. Significant clinical variability exists both between and within families.

 

Testing Options:

Several tests are available for the detection of carriers of, and individuals affected with, Tay-Sachs and Sandhoff diseases (see table below, Ordering Guidance, and Testing Algorithm). The recommended test for both diagnostic and carrier testing is NAGR / Hexosaminidase A and Total, Leukocytes/Molecular Reflex, Whole Blood. Testing begins with enzyme analysis and, when indicated, reflexes to the appropriate molecular analysis (either HEXA or HEXB gene), which includes sequencing and deletion/duplication analysis.

 

Follow-up molecular testing is recommended for all individuals with enzyme results in the carrier, possible carrier, or affected ranges. This differentiates between nondisease-causing pseudodeficiency alleles and disease-causing variants. In addition, molecular analysis allows for the facilitation of carrier testing and prenatal diagnosis for at-risk individuals.

 

For additional information on hexosaminidase test selection see Hexosaminidase Test Selection Quick-Reference Comparison.

Interpretation

Interpretation is provided with report.

Cautions

GM2 activator deficiency (AB variant, GM2A) is a rare disorder with clinical features similar to Tay-Sachs and Sandhoff diseases; however, levels of both hexosaminidase A and B are normal. GM2 activator deficiency is not detected with this assay. Molecular genetic analysis of GM2A is available; see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

Method Description

The substrate, 4-methylumbelliferyl-beta-D-N-acetyl-glucosamine-6-sulfate (4-MUGS), is highly specific for hexosaminidase A with minimal hydrolysis by placental hexosaminidase and none by hexosaminidase B. Hexosaminidase A hydrolyzes the 4-MUGS substrate, producing free 4-methylumbelliferyl, which fluoresces at an alkaline pH. Hexosaminidase A activity is determined by the amount of fluorescence produced.(Ben-Yoseph Y, Reid JE, Shapiro B, Nadler HL. Diagnosis and carrier detection of Tay-Sachs disease: direct determination of hexosaminidase A using 4-methylumbelliferyl derivatives of beta-N-acetylglucosamine-6-sulfate and beta-N-acetylgalactosamine-6-sulfate. Am J Hum Genet. 1985;37(4):733-740; Cowan T, Pasquali M. Laboratory Investigations of Inborn Errors of Metabolism. In: Sarafoglou K, Hoffman GF, Roth KS eds. Pediatric Endocrinology and Inborn Errors of Metabolism. 2nd ed. McGraw-Hill; 2017:1139-1158)

Report Available

2 to 8 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.